Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for OUD, based on a literature review and interviews with key informants in the field. The report describes 12 representative models of care for integrating MAT into primary care settings that could be considered for adaptation across diverse health care settings. 
Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for OUD, based on a literature review and interviews with key informants in the field. The report describes 12 representative models of care for integrating MAT into primary care settings that could be considered for adaptation across diverse health care settings. Common components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provider and community education, coordination and integration of OUD treatment with other medical and psychological needs, and psychosocial services and interventions. Models vary in how each component is implemented. Decisions about adopting MAT models of care should be individualized to address the unique milieu of each implementation setting. O pioid use disorder (OUD) is a national crisis in the United States (1) . In 2014, approximately 1.9 million Americans aged 12 years or older were estimated to have an OUD related to prescription opioids, and nearly 600 000 used heroin (2) . In 2013, an estimated 16 000 persons died as a result of prescription opioid overdose, and approximately 8000 died of heroin overdose (3) .
Medication-assisted treatment (MAT) for OUD, also referred to as "pharmacotherapy," decreases illicit opioid use, prevents relapse, improves health, and reduces the risk for death from OUD (4) . Medications approved by the U.S. Food and Drug Administration include a full agonist (methadone), partial opioid agonists (buprenorphine, buprenorphine-naloxone, and implantable buprenorphine), and opioid antagonists (oral and extended-release naltrexone). These medications block the euphoric and sedating effects of opioids, reduce craving for opioids, and mitigate opioid withdrawal symptoms. Medication-assisted treatment more effectively reduces opioid use than behavioral treatment alone (5, 6) . Behavioral therapy addresses the psychosocial contributors to OUD and may augment retention in treatment. The Office of National Drug Control Policy and the U.S. Department of Health and Human Services recently prioritized increasing access to MAT (1, 7) .
Integrating MAT into primary care settings expands access to OUD treatment (8) . The Drug Addiction Treatment Act of 2000 enabled physicians to prescribe buprenorphine for treatment of OUD, but its use remains limited (3, 9, 10) . Understanding the most effective and promising models of care is critical for optimizing initiatives to expand access to MAT (1) . Because not all MAT models are published and outcomes of different MAT models have not been compared, the Agency for e-mailed stakeholders about the opportunity to submit scientific information packets for ongoing or unpublished research. The literature review provided descriptive and contextual information on the models to supplement key informant interviews. The search identified 5892 abstracts; we reviewed 475 full-text articles (27 of which informed descriptions of MAT models of care) and 14 gray literature citations ( Table 2) .
Role of the Funding Source
This topic was selected by the AHRQ for systematic review by an Evidence-based Practice Center. A representative from the AHRQ who served as a Contracting Officer's Technical Representative provided technical assistance during the conduct of the full evidence review and provided comments on draft versions of the full evidence report. The AHRQ did not directly participate in the literature search; determination of study eligibility criteria; data analysis or interpretation; or preparation, review, or approval of the manuscript for publication.
RESULTS
Key informants consistently noted 4 key components of MAT models in primary care: pharmacotherapy with buprenorphine or naltrexone, provider and community educational interventions (such as inperson, Web-based, and telehealth provider continuing medical education [CME] activities; communitybased advertising campaigns; and stakeholder conferences), coordination and integration of OUD treatment with other medical and psychological needs, and psychosocial services (such as counseling on-site or by referral). Models varied in the degree of component implementation. Table 3 summarizes 12 representative models of MAT care and how the 4 key components are addressed. We included models that contained all 4 key components and that met criteria for effectiveness, innovation, and addressing special populations (for example, rural settings, patients with HIV, and prenatal care). Ten models were described by key informants, 6 were described in the published literature, and 7 were described in gray literature sources ( Table 2) . We categorized 4 models as primarily practice-based and 8 as systems-based, though most have elements of both. For each model, we discuss clinician-, practice-, and system-level factors, including financing, evidence of effectiveness, challenges, and situations in which the model is most likely to be feasible and effective.
Practice-Based Models

Office-Based Opioid Treatment
In office-based opioid treatment (OBOT), physicians who complete 8 hours of training and receive a Drug Enforcement Administration waiver number may prescribe buprenorphine-naloxone in the context of primary care (12, 13) . Although many providers offer OBOT without staff assistance, some practices designate a clinic staff member (often a nurse or social worker) to coordinate buprenorphine prescribing (14 -16) . Psychosocial services include brief counseling provided on-site by the physician or other staff and off-site referrals. Office-based opioid treatment is financed through provider reimbursement of billable visits. Medicare and many state Medicaid programs cover buprenorphine, though prior authorization is frequently required. The Providers' Clinical Support System for MAT (http://pcssmat.org), funded by the Substance Abuse and Mental Health Services Administration, is a free systems-level resource that supports OBOT implementation nationally with provider education and mentoring. Retention in treatment and opioid use outcomes with OBOT are similar to those in methadone treatment programs, with 38% retention at 2 years and 91% of urine toxicology screens negative for opioids among those retained in 1 long-term cohort study (14) .
Office-based opioid treatment may be particularly advantageous for reaching persons with OUD who are already engaged in primary care and offers an alternative for patients who cannot access methadone treatment programs. Challenges include a variable scope of psychosocial services and structure required for management of complex patients. Also, nurse practitioners and physician assistants-important providers of primary care in rural areas-are currently not eligible to prescribe buprenorphine.
Buprenorphine HIV Evaluation and Support Collaborative Model
The Buprenorphine HIV Evaluation and Support (BHIVES) Collaborative model adapted the OBOT framework to integrate buprenorphine treatment into primary care for HIV-infected patients (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Primary care providers in 9 HIV clinics provided buprenorphine, facilitated by a nonphysician coordinator and variable on-site psychosocial services. The BHIVES cohort of 303 participants receiving buprenorphine showed 49% treatment retention at 12 months, and opioid use in the previous 30 days decreased from 84% at baseline to 
One-Stop Shop Model
The one-stop shop model was developed in response to an outbreak of HIV infection in rural Indiana that was due to sharing infected syringes (32) where there were no existing OUD or HIV treatment services. Based in an existing mental health clinic, the model provides integrated care for HIV and hepatitis C virus infection, MAT, mental health, primary care, and syringe exchange (33) . A primary care provider embedded in the mental health clinic prescribes extendedrelease naltrexone and antiretroviral therapy. Financing is from a combination of existing Medicaid and federal funding. Although comprehensive care is attractive in any setting, this model might be particularly useful for quick deployment in other specific OUD and HIV outbreaks. However, it requires rapid training of willing local providers and state and federal resources for outbreak response, and its effect on outcomes and reproducibility in other settings have not been assessed. 
Integrated Prenatal Care and MAT
The integrated prenatal care model integrates buprenorphine treatment with primary and prenatal care for pregnant women with OUD. Office-based buprenorphine maintenance therapy is continued after delivery. Psychosocial services are provided on-site in some practices or through affiliated opioid treatment programs (OTPs). Although outcomes in primary carebased settings have not been assessed, outcome studies conducted in OTPs suggest a reduction in neonatal abstinence syndrome when pregnant women with OUD receive maintenance treatment with buprenorphine rather than methadone (34, 35) . This model is typically financed through existing Medicaid and other insurance reimbursement. Advantages include identification of women not previously engaged in OUD care, increased maternal motivation for OUD treatment due to concerns about the fetus, and provision of ongoing MAT maintenance in the postpartum period. A potential challenge is that the physician may reach their buprenorphine prescribing limit as more women seek to continue maintenance treatment after delivery.
Systems-Based Models
Medicaid Health Home Model
The Medicaid health home model is a flexible federal program through the Centers for Medicare & Medicaid Services that allows states that apply for a Medicaid waiver to integrate MAT and behavioral health therapies with primary care for patients with OUD (36, 37) . Primary care physicians prescribe buprenorphine as the primary pharmacotherapy, with financing through usual Medicaid coverage. Provider and community education (for example, provider outreach, CME conferences, and community advertising) is emphasized to increase uptake by clinicians and patients and to decrease stigma. Robust psychosocial services are required. Demonstrations in Rhode Island and Maryland implemented Medicaid health home models in OTPs or psychiatric clinics rather than in primary care clinic settings (37) . States determine the structure of health care delivery (for example, hub-and-spoke models in Vermont) and the approach to payment, which may include per-member, per-month payments (Maryland) and weekly bundled payments (Rhode Island) that fund care coordinators in addition to other billable health care services. Advantages include required care coordination and core psychosocial services, an emphasis on provider and community education, and flexibility in enabling service delivery and provision according to the needs and resources of a particular state. Medicaid health home models may be particularly wellsuited for states with a high prevalence of OUD and state governments seeking payment structures that promote broader integration of primary care, psychosocial, and MAT services for OUD.
Hub-and-Spoke Model
The hub-and-spoke model, developed in Vermont, triages patients to 2 levels of care on the basis of need during initial screening (38 -41). "Spokes" are primary care clinics that provide MAT for less complex patients by using an OBOT approach. "Hubs" are regional OTPs that care for more complex patients, dispense methadone if needed, support tapering off MAT, and provide consultative services to the spokes. Patients may transfer between a hub and a spoke on the basis of changing care needs.
Buprenorphine has been the primary pharmacotherapy in this model. Vermont incentivized implementation of buprenorphine prescribing by funding online buprenorphine waiver training for spoke physicians and other technical assistance. It also incentivized hubs by funding behavioral health specialists. Coordination and integration occur between the hub and the spoke and within each spoke and are typically carried out by a registered nurse or a case manager. Psychosocial services are embedded within spokes, including social workers, counselors, and community health teams. The model is financed through a Medicaid health home model waiver state block grant. Its effect on outcomes has not been published.
The hub-and-spoke model may be particularly well-suited for states with rural OUD populations where treatment services are limited. Important advantages include availability of tiered care and integration of primary care with regional OUD management expertise, use of care coordinators, and embedded psychosocial services at the spoke sites. Potential challenges include the unavailability of OTP hubs in all settings that wish to implement MAT.
Project Extension for Community Healthcare Outcomes
Project Extension for Community Healthcare Outcomes (ECHO) links primary care clinics in rural New Mexico with a university health system utilizing an Internet-based audiovisual network for mentoring and education (42) (43) (44) and has also been adapted to support rural primary care providers in MAT management. It emphasizes nurse practitioner-or physician assistantbased screening, with referral to a collaborating physician before initiation of MAT and for ongoing treatment. Counseling and behavioral therapies are offered by all ECHO team members during weekly teleconferences. Complex patients can be referred to an OTP. Project ECHO recruits physicians for buprenorphine waiver training and provision of CME in OUD management. The ECHO model may be considered a rural adaptation of the hub-and-spoke model or the collaborative opioid prescribing model. It is financed through various federal grants and Medicaid.
Patient-level outcomes have not been assessed, but the ECHO model has increased per capita numbers of rural primary care providers with buprenorphine prescribing waivers in New Mexico (42) . Advantages include a strong emphasis on psychosocial services, CME credits for teleconference participation, and collaboration with mid-level rural providers for initial screening. This model aims to enhance the capacity of rural primary care providers to treat OUD. Challenges include limited availability of face-to-face expertise in MAT for high-risk patients and a lack of direct contact between off-site experts and patients.
Collaborative Opioid Prescribing Model
The collaborative opioid prescribing model, developed in Maryland (45, 46) , is another tiered model of care with centralized initial intake, buprenorphine induction and stabilization at an OTP, and transfer to primary care clinicians for ongoing MAT. Unlike in the hub-and-spoke model, OTPs perform intake, induction, and stabilization in all patients and provide ongoing psychosocial services for patients transferred to primary care. Its effect on patient outcomes has not been assessed. This model is likely to be well-suited for primary care practices that are geographically close to OTPs. Financing is through Medicaid and private insurance. Advantages are similar to those of the hub-andspoke model, with the added benefit of ongoing OTP psychosocial services. Challenges include the geographic proximity required between OTPs and primary care sites and limited OTP capacity.
Massachusetts Nurse Care Manager Model
Massachusetts Medicaid reimburses nurse care managers in federally qualified health centers who are supporting physicians in the provision of buprenorphine or naltrexone for OUD treatment. The nurse care manager performs screening, intake, and education of patients and scheduling with a prescriber and facilitates ongoing medical and OUD management. The prescribing physician confirms the OUD diagnosis and appropriateness of MAT and comanages the patient with the nurse care manager. Psychosocial services are integrated on-site or nearby. Patients who require a higher level of care receive expedited OTP referral. The model is financed through direct Medicaid reimbursement to federally qualified health centers for nurse care manager time as a billable service, in addition to usual Medicaid coverage for pharmacotherapy and physician visits.
A pilot study of 408 patients enrolled in this program reported that 51% had received buprenorphine treatment at 1 year, and 91% of those retained on a regimen of buprenorphine at 12 months had urine toxicology screens that were negative for opioids (47) . Advantages include utilization of a skilled nonphysician to offload prescribing physician burden, an emphasis on provider training, and financial sustainability through Medicaid-reimbursed nurse care manager visits. This model may be attractive over a wide range of primary care practices in states with Medicaid programs or other payers that could adopt reimbursement of nurse care manager visits for OUD. An evaluation of statewide scale-up noted a 375% increase in the number of physicians with buprenorphine prescribing waivers within 3 years (48) . Challenges include variable availability of psychosocial services and nurse care managers and, in most states, a lack of Medicaid coverage for nurse care management of OUD.
Emergency Department Initiation of OBOT
This model focuses on emergency department (ED) identification of OUD and initiation of buprenorphine treatment (49) . Emergency department physicians assess patients for OUD and begin buprenorphine induction in appropriate candidates during their ED visit. Patients are discharged with instructions for continuation of home induction and stabilization doses and are connected to primary care OBOT for ongoing management. Brief physician counseling is performed during the ED visit, and other psychosocial services vary.
A randomized trial of ED-initiated buprenorphine treatment versus referral or brief intervention showed 78% engagement in buprenorphine treatment at 30 days compared with 37% in the referral group and 45% in the brief intervention group. The number of days of illicit opioid use per week decreased from 5.4 to 0.9 in the buprenorphine group versus 5.4 to 2.3 in the referral group and 5.6 to 2.4 in the brief intervention group (49) .
Medications, ED visits, and OBOT are funded through patient Medicaid and other insurance plans. This model is promising for scale-up to other ED settings with high prevalence of OUD and strong linkages to primary care OBOT. Advantages include enhanced access to MAT for patients who may not be accessing primary care or OTPs and improved engagement in OUD treatment compared with passive referral. Potential challenges include patient reliance on EDs to access treatment.
Inpatient Initiation of MAT
This model identifies OUDs among hospitalized patients, initiates MAT, and links to ongoing community-based treatment after discharge (50 -52) . Financing is from Medicaid and other insurance coverage, often requiring prior authorization for outpatient prescriptions before hospital discharge. Linkage with ongoing psychosocial services varies. In 1 study, 72% of inpatients with OUD who were randomly assigned to buprenorphine stabilization engaged in OBOT versus 12% of those randomly assigned to buprenorphine detoxification (50) . This model requires hospital support for inpatient consult services. Advantages include identification of patients with complex morbidity and high risk for death who may not otherwise access MAT, increased retention in care, and potential for linkage to OBOT for ongoing management. Patients initiating methadone treatment, which cannot be prescribed by primary care providers for OUD, would not be eligible for OBOT referral.
Southern Oregon Model
The Southern Oregon model is an example of a local, informal model for MAT delivery in a network of rural primary care clinics. It focuses on OBOT with buprenorphine and uses regular meetings of regional stakeholders, including regional Medicaid accountable care organizations (53) and primary care providers, for education, training, and development of practice standards around opioid prescribing for chronic pain and OUD treatment. Coordination or integration of care is variable and often limited, though an on-site clinical social worker is available in some clinics. The model is financed through direct support from accountable care organizations and usual fee-for-service billing.
The Southern Oregon model may be well-suited for rural health providers in states that have implemented the Patient Protection and Affordable Care Act and have accountable care organizations that can promote community-wide support for MAT. An advantage of this model is that it is community-based, which may help to overcome stigma and resistance to MAT use. Challenges include a lack of well-defined key components and limited psychosocial services and care coordination and integration.
DISCUSSION
Addressing the OUD epidemic in the United States will require diverse approaches over many years. We identified 12 representative models of integration of MAT into primary care that may be considered for adaptation and expansion across diverse health care settings.
All models contained some degree of 4 key components: pharmacologic therapy, psychosocial services, integration of care, and education and outreach. Models varied in their relative emphasis on these components, though common themes included the importance of a nonphysician coordinator and the use of tiered approaches. The ideal model of care for a particular setting likely depends on local factors, such as available expertise, the population, proximity to an addiction center of excellence, reimbursement policies, and geography. Decisions about MAT models of care should therefore be individualized to address the unique milieu of each implementation setting. It may be appropriate to combine elements of different models of care (for example, to implement care coordination by a nurse care manager within a hub-and-spoke model) or to link models of care (for example, ED-or inpatient-based screening and initiation of treatment linked with OBOT).
Ten of the 12 MAT models provided sublingual buprenorphine-naltrexone pharmacotherapy. Although implantable buprenorphine was approved by the U.S. Food and Drug Administration in 2016, research on its use in primary care settings is lacking. Two randomized trials showed efficacy of extended-release naltrexone for OUD in addiction treatment settings (54, 55) , but its effectiveness for OUD in primary care settings has not been studied and its use is limited. Expanding evidence-based, long-acting MAT options could broaden patient choice, reduce the risk for diversion, and decrease the need for frequent follow-up in appropriate patients.
Barriers to implementing MAT include a lack of trained primary care providers, reimbursement models that do not support care coordination and psychosocial services, persistent stigma associated with MAT, and long travel times for patients in rural areas (11) . Strategies to address these barriers include integration of training and education, use of nonphysicians, development of reimbursement models to support MAT delivery, use of tele-education, tiered care models, and stakeholder engagement.
Our report has potential limitations. The specific models described provide a representative taxonomy of ways to integrate MAT into primary care rather than an exhaustive list. No study has compared outcomes of different MAT models of care, and some models have not been reported in the published literature. Other challenges include overlapping characteristics of care models, variable levels of structure, and adaptation to specific settings.
Important areas of uncertainty include optimal methods for measuring quality of MAT care; assessment tools to better individualize care; optimal psychosocial components of MAT; cost and cost-effectiveness; methods for reducing diversion; optimal methods for coordination and integration of care; and the effectiveness of mid-level prescribing, newer MAT, and telehealth and telemedicine approaches (11) . Research in these areas is needed.
Existing MAT models of care can inform expanded implementation in primary care settings. Decisions about adopting MAT models of care should be individualized to address the unique milieu of each implementation setting.
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